DDInter405 DDInter927
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Clofarabine {u} (Compound) resembles {v} (Compound) Adenosine monophosphate
Clofarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Clofarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Clofarabine {u} (Compound) binds {v} (Gene) DCK
Clofarabine {u} (Compound) upregulates {v} (Gene) FAS
Clofarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Clofarabine {u} (Compound) downregulates {v} (Gene) ARL6IP1
Clofarabine {u} (Compound) causes {v} (Side Effect) Escherichia bacteraemia
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Clofarabine (Compound) resembles Adenosine monophosphate (Compound)
Clofarabine (Compound) resembles Nelarabine (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Clofarabine (Compound) treats hematologic cancer (Disease)
Clofarabine (Compound) binds DCK (Gene)
Clofarabine (Compound) upregulates FAS (Gene)
Clofarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Clofarabine (Compound) downregulates ARL6IP1 (Gene)
Clofarabine (Compound) causes Escherichia bacteraemia (Side Effect)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin